Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPA-TriMAR-T in HLA-A2+ gp100+ Malignant Melanoma
NCT03649529Phase 1Unknown
- Sponsor
- Timmune Biotech
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GPA-TriMAR-T cell in Malignant Melanoma (MM), sponsored by Timmune Biotech. Primary endpoint: Incidence of treatment-related adverse events at 24 months. Status: unknown.
02
Drugs
GPA-TriMAR-T cell
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03649529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649529.